These results indicate that NKP-1339/miR-142-NBs combined with US treatment can effectively induce ICD in tumor cells, mainly through CRT externalization, HMGB1 release, and the up-regulation of HSP70 and HSP90, thereby further activating antitumor immune responses. Here, HMGB1 is linked to neoplasm.